FibroBiologics, Inc. (NASDAQ: FBLG) is now covered by analysts at Maxim Group. They set a "buy" rating and a $12.00 price target on the stock.
FibroBiologics, Inc. (FBLG)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
FBLG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBLG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBLG alerts
High impacting FibroBiologics, Inc. news events
Weekly update
A roundup of the hottest topics
FBLG
News
- FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix MeetingGlobeNewswire
- FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics [Yahoo! Finance]Yahoo! Finance
- FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based TherapeuticsGlobeNewswire
- FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.MarketBeat
- FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing TherapeuticGlobeNewswire
FBLG
Earnings
- 11/12/24 - Beat
FBLG
Analyst Actions
- 2/13/25 - HC Wainwright
FBLG
Sec Filings
- 2/12/25 - Form SCHEDULE
- 2/11/25 - Form EFFECT
- 2/7/25 - Form 8-K
- FBLG's page on the SEC website